Drug Profile
Research programme: anti-complement component C5 minibodies - ADIENNE
Alternative Names: SAND 5; SAND 5 RGDLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ADIENNE
- Class Proteins
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glomerulonephritis; Haemolytic uraemic syndrome; Ischaemia; Reperfusion injury
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glomerulonephritis in Italy (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in Italy (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemia(Prevention) in Italy (Parenteral)